Material Weakness (removed) — Prior disclosure described ongoing remediation of material weaknesses in segregation of duties and bank reconciliation; current filing contains no such language, suggesting remediation complete though not explicitly stated.

NASDAQ: SILO Silo Pharma, Inc. 10-Q

SILO pivots to crypto & AI, delays drug IND, terminates key license amid control fixes

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 9, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SILO commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 2, 2026 4:16 PM